Alexion Pharma (NASDAQ: ALXN), a United States-based pharmaceutical company, has named Camilla Harder Hartvig as its new senior vice president and head of its EMEAC region, it was reported yesterday.
Hartvig will lead the commercial activities of the regional function from Alexion's EMEAC headquarters in Zurich, Switzerland, where she will succeed Christophe Bourdon who recently left the company to pursue a new opportunity.
Hartvig has more than 20 years' experience in the pharmaceutical industry and has worked in a broad range of companies, including AstraZeneca, Novartis and Allergan. Her expertise lies in a range of therapeutic areas such as cardiovascular, diabetes, respiratory, ophthalmology and oncology. She was most recently president, international markets at Glenmark Pharmaceuticals, where she led the commercial organisation across the European, Russian, Asian and Latin American regions.
The Nemours Children's Health System names new chair
Biopharma Veterans Kevin Young and Una Ryan Join Cortexyme Board of Directors
BioArctic reports approval by US FDA of Investigational New Drug Application for ABBV-0805
Seres Therapeutics Reports Corporate Changes to Focus on Advancing Clinical Assets
Hansa Biopharma names Donato Spota as new CFO
ESSA Pharma Inc incurs net loss of USD2.7m for Q1 fiscal 2018
Biogennix Names Baizer as Chief Financial Officer
Coro Health names new vice president of Business Development
KEPRO names new general counsel & chief compliance officer
Decibel Therapeutics Names Chief Medical Officer and Chief Operating Officer
VentureMed Group names new president and chief executive officer